๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

Long-term outcome of patients treated with terlipressin for types 1 and 2 hepatorenal syndrome

โœ Scribed by Adam G Testro; Sarah Wongseelashote; Peter W Angus; Paul J Gow

Book ID
108951622
Publisher
John Wiley and Sons
Year
2008
Tongue
English
Weight
199 KB
Volume
23
Category
Article
ISSN
0815-9319

No coin nor oath required. For personal study only.

๐Ÿ“œ SIMILAR VOLUMES

Predictors of response to therapy with t
Predictors of response to therapy with terlipressin and albumin in patients with cirrhosis and type 1 hepatorenal syndrome
โœ Andrรฉ Nazar; Gustavo Henrique Pereira; Mรณnica Guevara; Marta Martรญn-Llahi; Marie ๐Ÿ“‚ Article ๐Ÿ“… 2009 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 169 KB ๐Ÿ‘ 1 views

Terlipressin plus albumin is an effective treatment for type 1 hepatorenal syndrome (HRS), but approximately only half of the patients respond to this therapy. The aim of this study was to assess predictive factors of response to treatment with terlipressin and albumin in patients with type 1 HRS. T

Impact of liver transplantation on the s
Impact of liver transplantation on the survival of patients treated for hepatorenal syndrome type 1
โœ Thomas D. Boyer; Arun J. Sanyal; Guadalupe Garcia-Tsao; Frederick Regenstein; Lo ๐Ÿ“‚ Article ๐Ÿ“… 2011 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 191 KB

The development of hepatorenal syndrome type 1 (HRS1) is associated with a poor prognosis. Liver transplantation improves this prognosis, but the degree of the improvement is unclear. Most patients receive vasoconstrictors such as terlipressin before transplantation, and this may affect the posttran